Clec7a is a Potential Target to Relieve Neuropathic Pain Via Inhibiting Neuroinflammation Activation Through Regulating TLR4 Expression
Qiuyue Li,Yanqiong Zhang,Junfang Li,Yan Ma,Xiuying Liu,Fangbo Zhang,Jin Su,Xiujie Wang,Yi Zhang,Defeng Li,Feifei Guo,Ping Wang,Haiyu Xu,Hongjun Yang
DOI: https://doi.org/10.2139/ssrn.3361159
2019-01-01
SSRN Electronic Journal
Abstract:Background: The administration of neuropathic pain (NP) poses a major clinical challenge, since its complex mechanisms have not been fully elucidated. The aim of this study was to identify molecular changes associated with NP progression. Methods: NP-related differentially expressed genes (DEGs) in both dorsal root ganglion (DRG) and spinal cord (SC) were identified using microarray analysis based on chronic constriction injury (CCI) rat model. Then, a candidate signal axis involved into NP progression was screened by molecular interaction network analysis. Moreover, its roles in mechanical and thermal hyperalgesias of CCI rats, as well as in regulating downstream signaling were also determined in vivo. Findings: Among 92 DEGs in both DRG and SC between CCI and sham-operated rats, Clec7a was the only upregulated gene with fold change >4 after CCI insult, which were also verified by qPCR and Western blot. CCI modeling increased the number of GFAP/Clec7a and Iba-1/Clec7a positive astrocytes and microglias in both DRG and SC. In contrast, the intrathecal injection of Clec7a siRNA significantly increased the mechanical and thermal hyperalgesia of CCI rats. Mechanically, network and pathway analyses showed the involvement of Clec7a in Toll-like signaling pathway and its functional interaction with Toll-Like Receptor 4 (TLR4). Further experimental validation demonstrated that the knockdown of Clec7a markedly inhibited the expression of TLR4 and, consequently, reduced the release of pro-inflammatory cytokines including TNFα, IL-1β, and IL-6. Interpretation: Clec7a may be a potential target to relieve NP via inhibiting neuroinflammation activation through regulating TLR4 expression, suggesting a promising approach for NP therapy. Funding Statement: The funding sources of this study are from National Natural Science Foundation of China, the National Key Technology R & D Program of China, and National Key Research and Development Program of China. No study sponsors are involved in the research process of this project.Declaration of Interests: The authors declare that there is no conflict of interests regarding the publication of this paper.Ethics Approval Statement: All experimental protocols and animal-handling procedures were approved by our institutional Animal Care Committee and were performed in accordance with the recommendations outlined in the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.